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What is already known about the topic?
•• Advance Care Planning (ACP), here defined as an advance decision-making process involving a professionally facilitated 
conversation, has been proposed as a strategy to overcome the shortcomings of traditional advance directives.
•• Evidence is accumulating that facilitated ACP can strengthen patient autonomy and improve quality of care near the end of life.
•• It is yet unclear whether ACP may also reduce healthcare expenditures.
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Abstract
Background: While there is increasing evidence that Advance Care Planning has the potential to strengthen patient autonomy and 
improve quality of care near the end of life, it remains unclear whether it could also reduce net costs of care.
Aim: This study aims to describe the cost implications of Advance Care Planning programmes and discusses ethical conflicts arising 
in this context.
Design: We conducted a systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
statement.
Data sources: We systematically searched the databases PubMed, NHS EED, EURONHEED, Cochrane Library and EconLit. We 
included empirical studies (no limitation to study type) that investigated the cost implications of Advance Care Planning programmes 
involving professionally facilitated end-of-life discussions.
Results and discussion: Seven studies met our inclusion criteria. Four of them used a randomised controlled design, one used 
a before-after design and two were observational studies. Six studies found reductions in costs of care ranging from USD1041 to 
USD64,827 per patient, depending on the study period and the cost measurement.. One study detected no differences in costs. 
Studies varied considerably regarding the Advance Care Planning intervention, patient selection and costs measured which may 
explain some of the variations in findings.
Normative appraisal: Looking at the impact of Advance Care Planning on costs raises delicate ethical issues. Given the increasing 
pressure to reduce expenditures, there may be concerns that cost considerations could unduly influence the sensitive communication 
process, thus jeopardising patient autonomy. Safeguards are proposed to reduce these risks.
Conclusion: The limited data indicate net cost savings may be realised with Advance Care Planning. Methodologically robust trials with 
clearly defined Advance Care Planning interventions are needed to make the costs and returns of Advance Care Planning transparent.
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What this paper adds?
•• Findings indicate that facilitated ACP has the potential to reduce net costs of care.
•• The impact on costs of care may depend on the details of the ACP programme.
•• To protect end-of-life discussions from undue influences of cost considerations, adequate training of facilitators, clearly 
defined ACP standards and transparency concerning programme objectives and conflicts of interest should be ensured.
Implications for practice, theory or policy
•• Policy makers might consider investment in professionally facilitated ACP a good use of scarce healthcare resources if safe-
guards guarantee the openness of the planning process.
•• Methodologically robust trials are needed to determine which ACP elements are decisive for improving clinical outcomes and 
potentially reducing healthcare expenditures in accordance with patients’ preferences.
Introduction
Most healthcare systems in high-income countries face ris-
ing expenditures due to medical innovations and an 
increasing number of multimorbid, chronically ill patients 
in ageing societies. Empirical studies show that healthcare 
costs rise exponentially in the last year of life,1–5 while 
high-cost treatment near the end of life (EOL) may not 
improve quality of care.6,7 In addition, aggressive and 
expensive medical care is often inconsistent with the treat-
ment preferences of seriously ill patients.8
Decisions about life-sustaining treatment near the EOL 
often have to be made when patients lack decision-making 
capacity.9,10 Advance directives (ADs) have been proposed 
as a means to respect patients’ treatment preferences in these 
situations. As many people do not request all available life-
sustaining interventions,10,11 ADs have also been discussed 
– controversially – as a means to achieve cost savings at the 
EOL.12–15 ADs as legal documents, however, have fallen 
short of their high expectations.16–19 They are not widely 
used, not available when needed, often not relevant, of dubi-
ous validity and frequently not honoured by medical staff.20 
It is therefore not surprising that ADs also largely failed to 
reduce resource use and costs of care at the EOL.11,12,21–23
Over the last decades, however, the new concept of 
Advance Care Planning (ACP) has emerged.24,25 Instead of 
just completing and signing a legal form, ACP is under-
stood as a life-long communication process based on two 
fundamental components:25,26 (1) Specifically qualified 
healthcare professionals (‘facilitators’) assist individuals 
and their families/friends to develop, articulate and docu-
ment preferences for future medical care. (2) A systematic 
regional implementation ensures that the resulting plans 
are available and honoured reliably across all healthcare 
institutions in the community. A growing body of literature 
shows that these comprehensive ACP programmes are 
effective in increasing the number of meaningful and valid 
ADs,26 respecting patients’ treatment preferences near the 
EOL27 and improving quality of care for patients and their 
families.28 A recent systematic review found that complex 
ACP interventions (20 studies out of 113) may be more 
effective than ADs alone in improving compliance with 
patient’s EOL wishes and satisfaction with care.29
If such ACP programmes improve consistency between 
patients’ preferences and the delivered care, they could also 
have a larger impact on costs of care; at the same time, they 
require a considerable investment for implementation and 
maintenance. Systematic reviews have assessed the effects 
of ACP on other outcome parameters (e.g. reduction of hos-
pital days),29,30 and a recent review explored the economic 
evidence for ACP in a broad sense of the term that counts 
any completion of ADs as ACP.31 However, the available 
evidence on the specific cost effects of comprehensive ACP 
programmes based on a professionally facilitated commu-
nication process has never been evaluated systematically. 
We therefore conducted a systematic review on the cost 
implications of such comprehensive ACP programmes.
If ACP programmes turn out to reduce overall expendi-
tures and cost containment becomes an explicit goal of 
ACP, this raises delicate ethical issues.32,33 Given the 
increasing pressure to reduce healthcare expenditures, cost 
considerations could unduly influence the sensitive com-
munication process, thus jeopardising informed consent 
and patient autonomy.14 We have therefore added a section 
on the ethical implications because we consider it essential 
to openly address these ethical tensions – for the sake of 
patient autonomy.
Methods
We first developed an informal review protocol that was based 
on the Preferred Reporting Items For Systematic Reviews And 
Meta-Analyses (PRISMA) statement recommendations.34
Inclusion criteria
In accordance with the patients, interventions, compara-
tors, outcomes, study design (PICOS) approach, we used 
the following inclusion criteria. Patients: We included all 
patient groups. Interventions: A preliminary literature 
search revealed that hardly any studies had assessed the 
impact on costs of comprehensive ACP programmes with 
both a facilitated communication process and a system-
atic community implementation as described above. We 
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therefore decided to broaden the inclusion criterion to 
any intervention containing the first element of compre-
hensive ACP interventions: a communication process 
facilitated by a professional caregiver involving the 
patient and/or legal proxy about the patient’s preferences 
for future medical care. Comparators: We accepted any 
intervention as comparator. Outcomes: We included all 
studies that assessed healthcare costs or cost-effective-
ness as primary or secondary outcome measures. We 
excluded studies investigating other endpoints like hospi-
talisation rates or days spent in the intensive care unit 
(ICU) as mere indicators for cost reductions because such 
studies do not provide an account of the net resource use 
resulting from ACP interventions. Study design: We 
included all original empirical studies on cost effects of 
ACP. We did not restrict our search to prospective con-
trolled intervention studies to give a full overview of all 
studies conducted so far.
Search strategy and data sources
Our search strategy comprised terms describing the inter-
vention (ACP and its synonyms) and the outcome (costs 
and synonyms) linked by the Boolean operator ‘and’. The 
search strategy for PubMed is described in Table 1 and was 
adapted to the specificities of each database. We included 
studies published in English or German. Our search was 
conducted in April 2013. In addition to PubMed, we 
searched NHS EED, EURONHEED, the Cochrane Library 
and EconLit, as recommended.35 We also screened the ref-
erences of relevant articles we identified prior to and dur-
ing the literature search.
Study selection
Based on the inclusion criteria, two reviewers screened 
titles and abstracts of all articles independently. In case of 
disagreement, the inclusion was decided consensually 
within the research team. We then sought access via the 
local university and the Bavarian State Library for the arti-
cles that were considered potentially relevant after the first 
screening. The Bavarian State Library provides access to 
one of the most comprehensive online international jour-
nal collections as well as print media available in Germany. 
Authors were also contacted when necessary. The full texts 
were screened by G.M. and J.i.d.S. independently, and 
disagreement was resolved consensually. The screening 
and inclusion process is depicted in a flowchart as recom-
mended by the PRISMA statement (see Figure 1).
Data extraction and analysis
A data extraction tabloid was developed and tested. We 
extracted information on the following characteristics: 
study design, participants, intervention and comparator, 
outcome measure used, further effects measured, results 
and conclusion, and further information like funding 
source. C.K. extracted the data from studies meeting inclu-
sion criteria and assessed study quality, while G.M. 
reviewed her decisions. We considered data pooling in a 
meta-analysis inappropriate due to study heterogeneity in 
design, intervention, setting and outcome measures. We 
therefore preferred a narrative synthesis to describe the 
study results.
Results
The electronic database search yielded 852 potentially rel-
evant articles. Based on the inclusion criteria, we identi-
fied seven empirical studies assessing the costs of care 
with ACP in comparison with standard care, the first pub-
lished in 1994, the last in 2010 (see Table 2 for an over-
view of all studies). So far, no cost-effectiveness study on 
ACP has been published. 
Study quality
The seven studies varied considerably regarding study 
design, setting and participants, details of the intervention 
and cost components included in the assessment. Four 
studies used a randomised controlled trial design.38–41 The 
other three studies were more prone to risk of bias: One 
Table 1. Search strategy in PubMed.
Search strategy in PubMed
Intervention
  
1. (MeSH terms): Advance Care Planning (due to automatic explosion includes advance directives and living will) 
OR resuscitation order
2. (Title/abstract): resuscitation order* OR advance directive* OR advanced directive* OR advance care plan* 
OR advanced care plan* OR living will* OR end-of-life decision* OR end-of-life conversation* OR end-of-life 
discussion*
3. (1 OR 2)




5. (MeSH subheading): economics
6. (Title/abstract): cost* OR price* OR economic* OR resource* OR efficien*
7. (4 OR 5 OR 6)
 8. (3 AND 7)
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Figure 1. PRISMA 2009 flow diagram depicting the screening and inclusion process.
Source: Adapted from Moher et al.34
study used a before-after design37 and two used a cohort 
design (one prospective42 and one retrospective36).
Study setting and participants
The studies were conducted in quite different settings: six 
in the United States and one in Ontario, Canada.40 Three 
studies were performed in hospitals,36,41,42 one in nursing 
homes40 and three in home care settings.37–39 The studies 
were performed with different patient populations. Zhang 
et al. included patients suffering from advanced cancer 
(mostly lung, colorectal, breast and different gastro-intes-
tinal cancers), Edes et al. included patients with chronic 
obstructive pulmonary disease (COPD) and congestive 
heart failure (CHF) and Engelhardt et al. included COPD, 
CHF and cancer patients. The Study to Understand 
Prognoses and Preferences for Outcomes and Risks of 
Treatments (SUPPORT) study included patients suffering 
from one of nine life-threatening diseases, while Hamlet 
et al. included patients with heart failure and/or severe dia-
betes at high risk of death as identified by an EOL predic-
tive model. The other two studies did not limit their 
analysis to certain diagnostic groups. However, the largest 
classes of admitting diagnoses during last hospitalisation 
found by Chambers et al. were malignant neoplasms, res-
piratory diseases and cardiopulmonary diseases. See Table 
2 for further information on patient characteristics.
ACP intervention administered
The ACP interventions varied considerably among the 
seven studies and were often not described in sufficient 
detail. Some studies did not use the term ACP but rather 
talked about EOL discussion,42 discussion of ADs36,37 or 
EOL counselling.39 Only Molloy et al. implemented a 
comprehensive ACP programme (while calling it an 
‘advance directive programme’): In addition to facilitating 
EOL conversations, the project team educated the staff in 
the local hospitals and nursing homes about ADs and 
implemented routines for archiving and transferring the 
ADs across care settings. In all other studies, facilitated 
discussions of EOL issues were a core element of the ACP 
intervention without a systematic regional implementa-
tion. Nurses, nurse practitioners or social workers sup-
ported the discussions about EOL care and ADs. Most of 
them were specifically trained for this task;38–41 however, 
the content of the training sessions was not specified. In 
one study, the nurses conducted the EOL counselling via 
telephone,39 while in all other studies the advance planning 
conversations were led face to face. None of the papers 
clearly specified content, length and style of the conversa-
tions; often it was deliberately left open to the facilitators 
how to conduct the conversations.
In four studies, ACP was part of a more comprehen-
sive intervention to improve EOL care.37–39,41 The two 
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observational studies used indicators for the communica-
tion process as they did not implement the intervention 
themselves. Chambers et al. assumed the presence of 
EOL conversations if a discussion of the patient’s AD 
within the first 48 h after admission had been docu-
mented. Zhang et al. asked the patients whether they had 
discussions with their physicians about EOL care.
Cost data analysed
The cost components included in the calculations also varied 
considerably between the seven studies. None of the studies 
assessed overall costs for the healthcare system. Costs accru-
ing outside the healthcare system to family and friends from 
providing care themselves were also never included in the 
calculations. The most comprehensive cost assessment was 
performed by Engelhardt et al. who gathered cost data on 
inpatient, outpatient, nursing home and inpatient hospice 
care as well as other cost components (e.g. diagnostic ser-
vices, prosthetics and administrative overhead). Zhang et al. 
only included costs for hospitalisation, hospice care and life-
sustaining procedures thereby excluding costs, for example, 
for outpatient or home care. Edes et al. incorporated costs of 
inpatient and outpatient care including allied health and 
ancillary services, but excluded costs for medication. Hamlet 
et al. included all Medicare costs, but did not collect cost data 
incurred after hospice enrolment. The SUPPORT study as 
well as Chambers et al. focused on inpatient costs ignoring 
outpatient and other care costs. Molloy et al. collected data 
on hospitalisation and nursing home drug costs and included 
the programme costs, but did not consider costs of nursing 
home care and outpatient physician services.
Only three studies included the costs of the intervention 
in their calculation,37,38,40 thus allowing an assessment of 
the net cost savings. It is often not clearly stated whether 
all costs or only costs arising for the payer/insurer were 
incorporated in the calculation with the exception of Zhang 
et al. and Hamlet et al. who chose the payer’s perspective. 
The time frames for the cost measurement also differed 
considerably ranging from 1 week before death42 over 
6 months37,39 to 18 months40 after implementing the inter-
vention. Engelhardt et al. do not explicitly report the time 
frame of their cost calculation, while Chambers et al. and 
the SUPPORT study calculated the costs during one hospi-
tal stay. Furthermore, the studies used different approaches 
for calculating the included cost components.
Effects of ACP on costs
Except for the SUPPORT trial, all studies found reduced 
costs through the professionally facilitated discussions 
about future medical care, three of them statistically sig-
nificant (p-value ⩽ 0.05).39,40,42 One study showed a non-
significant gross cost reduction,38 while the remaining two 
studies did not report whether the cost reductions reached 
statistical significance. Chambers et al. found the relation-
ship between costs and AD discussions to be statistically 
significant in the logistic regression.
The reported cost reductions range from USD1041 to 
USD64,827 per patient. These figures cannot be compared 
(let alone pooled in a meta-analysis), however, because the 
studies differ substantially with respect to the costs included 
in the calculation, the time frame of analysis and the patient 
population, setting and intervention chosen for the respec-
tive study. Yet, an overall appraisal of these figures and 
their respective frames of reference indicates that cost sav-
ings of ACP programmes may be substantial: The relative 
cost reduction ranged from 68%36 to 5%.39 The two highest 
cost reductions, both absolute and relative, were achieved 
in rather sick patient populations who used a considerable 
amount of hospital care.36,37 Only three studies reported the 
costs of implementing facilitated ACP conversations. In the 
study of Edes et al., programme costs amounted to 
USD1968 per patient with a net saving of USD11,239 per 
patient over 6 months. Molloy et al. found a net cost reduc-
tion of CAD1748 per resident with programme implemen-
tation costs of CAD113 per resident. In the study of 
Engelhardt et al., the programme costs were USD452 per 
case compared to gross savings of USD4172 per patient.
Discussion
Key findings
To our knowledge, this is the first systematic review evalu-
ating the cost implications of ACP, operationalised as at 
least comprising one professionally facilitated conversation 
about individuals’ preferences for future medical care. 
While traditional ADs, merely understood as the presence of 
a signed legal document, have not been found to reduce 
costs consistently,12,21,23,31 six of the seven studies included 
in this review demonstrated cost savings through ACP rang-
ing from USD1041 to USD64,830 per patient, depending on 
the study period and the cost measurement. Programme 
implementation costs were small compared to savings real-
ised, amounting to 6%, 11% and 15% of gross savings. 
However, the results of this review have to be interpreted 
with caution as the studies varied considerably with respect 
to study design, ACP intervention, setting, patient selection 
and cost components included. None of the studies provided 
a comprehensive cost-effectiveness analysis of ACP.
Relation between effectiveness and cost impact 
of ACP
Can we conclude that ACP programmes with qualified 
facilitation reduce costs? Not from the SUPPORT study. 
However, leaving aside that SUPPORT estimated costs 
using an algorithm based on prior research which might 
be less reliable, another observation warrants some thoughts: 
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The SUPPORT study was disappointingly ineffective in 
reaching any of its goals (like increasing the completion 
of ADs or improving physicians’ understanding of patient 
preferences). The other six studies were more successful 
on all outcome parameters, not just costs. It seems evident 
that an intervention which is ineffective in reaching its 
primary goals cannot lead to any cost reductions. But why 
did the SUPPORT study fail? A potential explanation 
could be the lack of standards for the ACP intervention: 
content and style of communication, training of facilita-
tors and essential components of a regional implementa-
tion all remained vague. Apparently, the details of the 
ACP programme’s structure and realisation matter: We 
need to understand better, therefore, which specific ele-
ments make ACP programmes effective in eliciting and 
respecting patients’ treatment preferences and conse-
quently might lead to cost reductions.
In most studies, however, ACP was part of a more com-
prehensive intervention to improve communication and 
EOL care. It therefore remains unclear which part of the 
intervention was responsible for the observed cost reduc-
tions. Only one intervention study40 and the two observa-
tional studies36,42 assessed the specific cost effects of ACP 
in isolation and are therefore able to attribute the observed 
cost reductions to the ACP intervention. The evidence, 
however, is limited by a small sample size40 or by the 
observational study design and the inability to control the 
intervention.36,42 In addition, the two observational studies 
did not include the costs for ACP, and it is therefore unclear 
whether the savings at the EOL can offset costs for EOL 
conversations, although the cost savings in Chambers 
et al.’s study are big enough to assume that they would 
exceed any costs for communicative interventions. The 
strengths of Molloy et al.’s study are the randomised con-
trolled design and the comprehensive cost assessment, 
although they apparently excluded outpatient physician 
costs. Overall, the evidence base remains limited and no 
final conclusion can be drawn regarding the cost implica-
tions of ACP; especially Molloy et al.’s study, however, 
seems to justify the hypothesis that ACP may be able to 
reduce costs of care at the EOL.
Limitations of the review and generalisability of 
results
Our review has several limitations. First, it was difficult 
to identify ACP programmes because there is no estab-
lished common understanding of ‘ACP’. On the one 
hand, the term ‘ACP’ referred to a wide spectrum of phe-
nomena ranging from merely signing AD documents to 
fully fletched ACP programmes with a regionally imple-
mented, professionally facilitated communication pro-
cess. On the other hand, the ACP elements were often 
integrated into a wide variety of communicative inter-
ventions with different overriding goals. We tried to be 
rather broad in our search strategy, but still may not have 
captured all relevant articles. Furthermore, we may have 
missed potentially interesting studies due to our limita-
tion to articles published in English or German. Finally, 
we were not able to access two potentially relevant arti-
cles43,44 for full-text screening.
With respect to the generalisability of the results, it can 
be questioned whether the observed effects can be repli-
cated in other settings. The observed cost savings of ACP 
may depend on the structure of the healthcare systems and 
the cultural background which determines personal prefer-
ences and values: If individuals, for example, request all 
possible life-sustaining treatments for religious reasons, 
ACP will not reduce costs of care. Most studies were con-
ducted in the United States with an overall high level of 
healthcare spending and an individualistic culture. It there-
fore remains unclear whether the same effects could be 
observed in national healthcare systems with lower overall 
healthcare expenditures or other cultural preferences. This 
is supported by another study,45 which found that ADs are 
associated with lower levels of Medicare spending only in 
regions with comparatively high levels of EOL expendi-
tures. In regions where expenditures were already low, 
ADs seemed to have no effect on healthcare costs.
Implications for future research
First, the cost effects of ACP should be studied in other set-
tings outside the United States or Canada, especially in 
healthcare systems with lower levels of spending and 
stricter cost-control policies. In addition, methodologically 
robust randomised controlled intervention trials of ACP are 
necessary that employ a comprehensive, validated ACP 
approach (including facilitated EOL conversations and a 
regional implementation) to accurately assess programme 
costs, cost savings and clinical outcomes (e.g. efficacy). It 
might be difficult to estimate the full impact of ACP on 
costs because cost reductions may be realised in one health-
care sector (e.g. intensive care) while additional costs arise 
in another sector (e.g. hospice care and nursing homes), but 
efforts should be made to make those effects visible in 
future studies evaluating costs and returns of ACP.
Furthermore, the reporting of such studies has to be 
improved: Questions that need to be addressed are:46,47 
Which perspective is chosen (societal, healthcare system, 
payer, etc.)? What cost components are included in the 
analysis? How are costs calculated (measurement of 
resource consumption, estimation of prices)? Were 
adjustments made (e.g. for market imperfections)? 
Consolidated reporting standards for health economic 
evaluations have been published in 2013 and give helpful 
guidance to future authors.48 Likewise, the ACP interven-
tions should be explicitly defined and described in suffi-
cient detail to allow an assessment of which elements 
determine ACP effectiveness.
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Ethical considerations
This review provides preliminary empirical evidence that 
ACP programmes with facilitated EOL discussions may 
offset their costs or even produce net cost savings near the 
EOL. It therefore might appear an attractive tool for payers 
and policy makers at different levels of the healthcare sys-
tem. From an ethical standpoint, however, it is questiona-
ble whether reducing costs of care should be a reason for 
implementing ACP interventions. At the surface, this does 
not appear to be a problem, on the contrary: Where else in 
highly developed healthcare systems can we strengthen 
patient autonomy, improve quality of care and save a con-
siderable amount of resources at the same time? It seems 
that the cost argument just strengthens the case for imple-
menting ACP programmes.
Risks for patient autonomy and patient-centred 
care
At a closer look, however, the relationship between ACP 
and costs of care is much more delicate involving a con-
siderable potential for ethical conflict. ACP programmes 
will only reduce healthcare expenditures if patients opt 
for limiting life-sustaining treatment. Consequently, there 
is no firm and systematic link between ACP and net cost 
savings. Under economic pressure, the primary goal of 
ACP – promoting patient-centred care near the EOL – 
could therefore compete with the goal of reducing health-
care expenditures. Facilitators might be incentivised to 
advise individuals to choose less invasive and therefore 
less costly treatment in their ADs. At the same time, facili-
tators employed by a certain institution (e.g. a nursing 
home or a hospital) could be tempted to push individuals 
towards advance treatment decisions that are likely to 
increase the revenues of their respective institution. These 
conflicts of interest jeopardise the openness of the com-
munication process as individuals may be unduly influ-
enced to choose more limited or more extensive care than 
truly desired.14 A proliferating suspicion of biased ACP 
conversations will erode patient trust in the process and 
prompt fears of undertreatment which could eventually 
undermine the efforts to introduce ACP into regular health 
care.32,49,50
Managing the risks
In light of these concerns, ACP must remain an instrument 
to ensure that patients’ wishes are honoured reliably when 
they have lost decision-making capacity, irrespective of 
the effects on the costs of care. However, costs of care are 
an important driver for payers and policy makers, and it 
would therefore be naïve not to take into account that cost 
containment may also be a reason for implementing ACP. 
In Australia, for example, ACP in residential homes for the 
elderly was funded in order to reduce hospital days for 
acute care.33 Policy makers should therefore openly 
acknowledge the potential interference with patient auton-
omy and introduce safeguards to ensure the openness of 
the ACP process:32,49,50 (1) make programme objectives 
and potential conflicts of interest transparent, (2) ensure 
adequate training and supervision of facilitators, (3) estab-
lish clearly defined standards for the facilitation process to 
guarantee its high quality and (4) educate facilitators to 
identify and manage conflicts of interest.
Conclusion
The studies included in this review allow only preliminary 
conclusions regarding the cost implications of ACP 
because of poorly defined and heterogeneous interventions 
and incomplete cost assessments. The available evidence, 
however, indicates that ACP may reduce net health expen-
ditures – despite the costs of implementation and mainte-
nance. Methodologically rigorous prospective intervention 
trials are necessary to produce more reliable evidence 
about the cost implications of ACP and to identify those 
ACP elements that are essential for improving clinical out-
comes and possibly reducing net healthcare expenditures. 
The ethical tension between the primary goal of ACP, pro-
moting patient autonomy and patient-centred care, and the 
goal of reducing costs of care requires certain safeguards 
– above all ensuring the quality of the facilitation process. 
It therefore should be a priority to develop evidence-based 
standards for comprehensive ACP programmes that effec-
tively align the care delivered near the EOL with patients’ 
preferences.
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